Abstract
Heart failure is a common condition, associated with both poor prognosis and poor quality of life. In contrast to all other cardiovascular diseases, the prevalence of heart failure is increasing in the western world, and is likely to continue to do so as the population ages. In the UK, a significant proportion of patients with heart failure come from South Asian and African Caribbean ethnic groups. A large body of evidence exists that there may be epidemiological and pathophysiological differences between patients with heart failure from different ethnic groups. Treatments such as ACE inhibitors, which are now part of standard heart failure therapy, have an evidence base consisting of trials in patients of almost exclusively white ethnicity. Such treatments may not be equally effective in patients from other ethnic groups. This review will discuss the current evidence for heart failure management with respect to ethnicity, and consider the implications for future drug development and implications for antihypertensive therapy.
Keywords: heart failure, breast cancer, angiotensin converting enzyme (ace) inhibitors, hypertension, type II diabetes mellitus, coronary atherosclerosis
Current Pharmaceutical Design
Title: Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Volume: 10 Issue: 29
Author(s): Michael D. Sosin, Gurbir S. Bhatia, Gregory Y.H. Lip and Russell C. Davis
Affiliation:
Keywords: heart failure, breast cancer, angiotensin converting enzyme (ace) inhibitors, hypertension, type II diabetes mellitus, coronary atherosclerosis
Abstract: Heart failure is a common condition, associated with both poor prognosis and poor quality of life. In contrast to all other cardiovascular diseases, the prevalence of heart failure is increasing in the western world, and is likely to continue to do so as the population ages. In the UK, a significant proportion of patients with heart failure come from South Asian and African Caribbean ethnic groups. A large body of evidence exists that there may be epidemiological and pathophysiological differences between patients with heart failure from different ethnic groups. Treatments such as ACE inhibitors, which are now part of standard heart failure therapy, have an evidence base consisting of trials in patients of almost exclusively white ethnicity. Such treatments may not be equally effective in patients from other ethnic groups. This review will discuss the current evidence for heart failure management with respect to ethnicity, and consider the implications for future drug development and implications for antihypertensive therapy.
Export Options
About this article
Cite this article as:
Sosin D. Michael, Bhatia S. Gurbir, Lip Y.H. Gregory and Davis C. Russell, Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension, Current Pharmaceutical Design 2004; 10 (29) . https://dx.doi.org/10.2174/1381612043382783
DOI https://dx.doi.org/10.2174/1381612043382783 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of (Modified) Lipoproteins in Vascular Function: A Duet Between Monocytes and the Endothelium
Current Medicinal Chemistry The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Current Drug Targets Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews Growth Hormone Secretagogues
Combinatorial Chemistry & High Throughput Screening The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis
Current Pharmaceutical Design Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Effect of Chronic Co-Administration of Morphine and Verapamil on Isoproterenol-Induced Heart Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Glibenclamide Action on Myocardial Function and Arrhythmia Incidence in the Healthy and Diabetic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury
Current Vascular Pharmacology